返回ChemicalBook首页>CAS数据库列表>2614-06-4

2614-06-4

中文名称 (+)-沙利度胺
英文名称 (R)-(+)-THALIDOMIDE
CAS 2614-06-4
分子式 C13H10N2O4
分子量 258.23
MOL 文件 2614-06-4.mol
2614-06-4 结构式 2614-06-4 结构式

基本信息

中文别名
(+)-沙利度胺
酞咪呱啶酮(反应停)
英文别名
NSC 91729
(R)-(+)-THALIDOMIDE
6-dioxo-3-piperidyl)-n-(d-(+)-phthalimid
N-[(R)-2,6-Dioxopiperidine-3-yl]phthalimide
(+)-N-[(R)-2,6-Dioxo-3-piperidinyl]phthalimide
6-dioxo-3-piperidinyl)-3(2h)-dion(r)-1h-isoindole-2-(2
(3R)-3-(1,3-Dioxo-2H-isoindole-2-yl)piperidine-2,6-dione
(R)-2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3-(2H)-DIONE
R-(+)-2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3(2H)-DIONE
(+)-2-[(R)-2,6-Dioxo-3-piperidinyl]-1H-isoindole-1,3(2H)-dione

物理化学性质

熔点269-271°C
沸点401.48°C (rough estimate)
密度1.2944 (rough estimate)
折射率1.5300 (estimate)
储存条件-20?C Freezer
溶解度DMSO: soluble
酸度系数(pKa)10.70±0.40(Predicted)
形态solid
颜色white

安全数据

危险性符号(GHS)GHS hazard pictogramsGHS hazard pictograms
GHS07,GHS08
警示词危险
危险性描述H302-H360
危险品标志T
危险类别码61-22
安全说明53-36/37/39-45
WGK Germany3
RTECS号TI4925000
(+)-沙利度胺价格(试剂级)
报价日期产品编号产品名称CAS号包装价格
2025/02/08HY-14658B(+)-沙利度胺
(R)-Thalidomide
2614-06-45 mg1729元
2025/02/08HY-14658B(+)-沙利度胺
(R)-Thalidomide
2614-06-410 mg2765元

常见问题列表

生物活性
(R)-Thalidomide ((R)-(+)-Thalidomide) 是 Thalidomide 的 R-对映异构体。(R)-Thalidomide 具有镇静作用。
体外研究

The transport of the (R)-Thalidomide from the R-imprinted MIP-1 through the donor phase to the receiver phase is much less owing to the stronger retention of the thalidomide in the organic phase. With the affinity of (R)-Thalidomide by the MIP present surface capture, that is more strongly than the other forms. In the case of (R)-Thalidomide, it is found to bind to the selective sites of the MIP more strongly than the other which reflects their different biological entities.
The (S)-Thalidomide imprints MIP nanoparticles exerted a greater cytotoxic effect on the caco-2 cells than the (R)-Thalidomide imprinted MIPs.

体内研究

Adult female F344 rats are implanted with 9L gliosarcoma tumours intracranially, subcutaneously (flank), or both. Effectiveness of oral thalidomide alone, and with intraperitoneal BCNU or cisplatin combination chemotherapy, is assessed after several weeks treatment. Both serum and tissue concentrations of (R)-thalidomide are 40-50% greater than those of (S)-thalidomide. Co-administration of BCNU or cisplatin with thalidomide did not alter the concentration enantioselectivity.

"2614-06-4" 相关产品信息
127294-73-9 54012-73-6 50-35-1 50534-49-1